| Field | Specification |
|---|---|
| Target | |
| Species | |
| Applications | |
| Tag | |
| Expression system | |
| Expression region | |
| Molecular weight | |
| Purity | |
| Biological activity | |
| Endotoxin level | |
| Animal origin-free | |
| Reconstitution | |
| Formulation | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Recombinant Human IL-6 Protein is a full-length, glycosylated monomer expressed in human cells. It is manufactured in an animal-free, xeno-free and tag-free format and supplied lyophilized without carrier protein, at >95% purity by SDS-PAGE and endotoxin <0.5 EU/µg.
Typical research uses include JAK/STAT3 activation through IL-6R and gp130, the late stages of B-cell maturation into antibody-secreting cells, chosen hematopoietic and myeloid differentiation protocols, and models of acute-phase and inflammatory responses. Expression in human cells supports mammalian glycosylation, activity is confirmed by TF-1 cell proliferation, and one peer-reviewed study reports the use of this IL-6.
Expression system: Human cells · Tag-free · Animal-free
Scientific Background
IL-6 is a pleiotropic, glycosylated cytokine produced by immune and stromal cell types. It binds membrane-bound or soluble IL-6R, forms a complex with gp130 and activates JAK/STAT3, MAPK and PI3K pathways.
Its roles span B-cell maturation and other immune-cell differentiation steps, the acute-phase response, hematopoietic progenitor biology and inflammatory programs that differ between tissues. Because it can act through both classical signaling and trans-signaling, experiments should distinguish the two; the outcome depends on IL-6R and soluble receptor availability, gp130, cell state, dose and exposure time.
Research Applications
IL-6 is used in signaling, immune-cell and hematopoietic research, and as a defined stimulus for TF-1 bioassays. The table summarizes typical workflow placement; it is a planning guide, not a universal protocol.
| Application | Role of IL-6 | Companion signals and context | Suggested readouts |
|---|---|---|---|
| TF-1 bioassay | Dose-dependent proliferation | Defined assay medium | Proliferation and relative potency |
| B-cell study | Differentiation support | Activation and companion cytokines | CD38, CD138, immunoglobulin secretion |
| Hepatocyte response | Acute-phase signaling | Time course and receptor context | pSTAT3, CRP, SAA genes |
| Myeloid/DC workflow | Maturation-associated signal | GM-CSF/IL-4 and maturation cocktail | Phenotype, cytokines, antigen presentation |
Planning considerations
- Confirm the responsive cell stage and receptor context, including membrane IL-6R versus soluble IL-6R.
- Use a published or internally validated protocol as the starting point and optimize the dose range in the chosen model.
- Control timing, medium, matrix and companion factors, and include vehicle/no-factor and pathway-response controls.
- Measure phenotype and function rather than cell number alone. No EC50 or universal working concentration is published.
Protein Specifications
| Target | IL-6 |
|---|---|
| Alternative names | Interleukin-6 |
| Species | Human |
| Expression system | Human cells |
| Structure | Glycosylated monomer |
| Protein family | Interleukin |
| Expression region | Full length |
| Tag | Tag-free |
| Animal origin | Animal-free / xeno-free |
| Molecular weight | 26–30 kDa. Refer to the lot-specific Certificate of Analysis (CoA) for lot data. |
| Purity | >95% by SDS-PAGE |
| Endotoxin level | <0.5 EU/µg |
| Formulation | Lyophilized from a 0.2 µm-filtered solution in PBS without carrier protein |
| Form | Lyophilized |
| Biological activity | Stimulation of human TF-1 cell proliferation |
| Applications | Stem Cell Differentiation, Immunotherapy, Cell Signaling Studies, Cell Proliferation, Hematopoietic Differentiation |
Biological Activity & Quality Control
Biological activity is evaluated by stimulation of human TF-1 cell proliferation.
Lot-specific activity and purity data are provided on the Certificate of Analysis (CoA), available from BioHippo on request.
Reconstitution
- Briefly centrifuge the vial before opening.
- Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.
- Mix gently and prepare single-use aliquots.
- Avoid repeated freeze–thaw cycles; a manual-defrost freezer is recommended.
Storage & Shipping
| Storage | As supplied: −20°C to −80°C for up to 12 months from receipt. After reconstitution: 2°C to 8°C for up to 1 month, or −20°C to −80°C for up to 3 months, under sterile conditions. Avoid repeated freeze–thaw cycles. |
|---|---|
| Shipping | Please contact us to confirm shipping conditions for this product. |
Selected References
- Yasukawa K, Hirano T, Watanabe Y, et al. (1987) Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 6:2939-2945. 10.1002/j.1460-2075.1987.tb02598.x
- Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6:a016295. 10.1101/cshperspect.a016295
- Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448-457. 10.1038/ni.3153
Safety & Handling
Handle as a laboratory reagent and consult the linked SDS before use. Avoid repeated freeze–thaw cycles of the reconstituted protein.
For research use only. Not for diagnostic or therapeutic use.
Can't Find What You're Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Wang X, et al. (2018) Dendritic Cells Are Critical for the Activation and Expansion of Vδ2+ T Cells After Allogeneic Hematopoietic Transplantation. Front Immunol 9:2528. 10.3389/fimmu.2018.02528